BioSpace News Archive

Ryvu Therapeutics, a clinical stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, will present data from its multiple oncology programs at the upcoming American Association for Cancer Research Virtual Annual Meeting II taking place June 22 to June 24, 2020.

CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, announced that one of its first-in-class drug candidates, CT041 humanized anti-claudin18.2 autologous Chimeric Antigen Receptor T Cells for the treatment of patients with claudin18.2-positive adenocarcinoma of the stomach, gastroesophageal junction, or pancreas, has received Investigational New Drug clearance from the United States Food and Drug Administration.

OneOncology, the national network of independent community oncologists, announced a new partnership with The Center for Cancer and Blood Disorders in North Texas as the oncology network expands its footprint in the southwest.

Data Presented at American Urological Association 2020 Virtual Experience Highlight Benefits and Superior Sexual Function* Preservation of the Minimally Invasive Treatment for Patients with Enlarged Prostate

New data provide proof-of-concept for VBL’s proprietary MOSPD2 bi-specific antibodies, observing survival benefit and no evidence of toxicity in a model of metastatic human cervical cancer

Kraig Biocraft Laboratories, Inc. announces that the Company’s Board of Directors held its first meeting with its four new members-elect in attendance.

Amivantamab-treated patients achieved durable remissions in CHRYSALIS study; data will be presented during ASCO Virtual Scientific Program [18-May-2020] RARITAN, N.J. , May 18, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the Phase 1 CHRYSALIS study ( NCT02609776 ) evaluating amivantamab (JNJ-6372) in

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced that the Phase 1 study of ALX148 in patients with relapsed/refractory Non-Hodgkin Lymphoma has been selected for an e-Poster presentation at the Virtual 25th Annual Congress of EHA, June 11 – 14, 2020.

Financing Supports Ongoing Phase 1 Trial of SQZ APC Platform in HPV+ Tumors and Advancement of SQZ AAC Platform towards an Investigational New Drug Application

AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® has been granted Breakthrough Therapy Designation in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.